Future Outlook of the Daratumumab Or Darzalex Market: Growth, Trends, and Emerging Opportunities Explored
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Expected Growth Rate of the Daratumumab Or Darzalex Market Based on Industry Projections?
The growth of the daratumumab or darzalex market has been swift and significant in recent times. It’s projected to expand from $5,093.04 million in 2024 to $5,618.30 million in 2025, with a compound annual growth rate (CAGR) of 10.3%. The growth that was observed in the historical period can be linked to the use of various avenues of research, enhanced efficiency in biomanufacturing operations, augmented usage of monoclonal antibodies, a rise in the number of strategic initiatives, as well as increased mAbs secretion.
Expectations indicate that the daratumumab or darzalex market is set to experience robust expansion in the impending years. The market is projected to reach $8,189.36 million by 2029 with a compound annual growth rate (CAGR) of 10.0%. Aspects such as increasing empirical proof, its wider application in earlier stages of treatment, the rising need for biologics, elevated patient consciousness, growth in blood cancer diagnoses, and the higher occurrence of chronic diseases have been identified as the major contributors to growth in the forecast period. The period is also likely to witness significant trends including technological progression, launching of new products, product and service offerings, partnerships, mergers, acquisitions, advancements in radiation procedures, and collaborative efforts.
How Are the key drivers expanding the growth of the Daratumumab Or Darzalex Market?
A surge in the number of bone marrow cancer cases is anticipated to spur the daratumumab or darzalex market’s expansion. Bone marrow cancers, such as multiple myeloma and leukemia, originate within the bone marrow and cause abnormal blood cell production that disrupts the body’s standard functioning. The escalating figures of bone marrow cancer are linked to an aging demographic, enhanced diagnostic techniques, and contributory aspects such as environmental impacts, lifestyle decisions, and genetically inherited risks. Daratumumab (Darzalex) is used in treating multiple myeloma, a kind of bone marrow cancer, by eliminating irregular plasma cells within the bone marrow. For example, in January 2024, the American Cancer Society, a US-based not-for-profit committed to abolishing cancer, predicted 89,190 lymphoma incidences compared to 89,010 in 2022, and also 35,780 instances of myeloma as opposed to 34,470 in 2022. Consequently, the surge in bone marrow cancer frequency is propelling the daratumumab or darzalex market’s expansion.
Get Your Free Sample of the Global Daratumumab Or Darzalex Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp
What Companies Are At the Forefront of Innovation in the Daratumumab Or Darzalex Market?
Major companies operating in the daratumumab or darzalex market include Genmab A/S, Janssen Biotech Inc.
How Are Emerging Trends in Consumer Behavior Affecting the Daratumumab Or Darzalex Market?
The dominant trend in the daratumumab or darzalex market involves a shift towards early intervention in oncology treatments, particularly through combination therapies to improve efficiency in combating multiple myeloma and other forms of cancer. Combination therapies deploy two or more treatment agents that work in different ways and often synergistically, enhancing effectiveness, curtailing resistance, improving patient results, and potentially mitigating negative side effects compared to single-agent therapy. To illustrate, in July 2024, the U.S. pharmaceutical company Johnson & Johnson secured U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to be used in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) as induction and consolidation treatment for patients newly diagnosed with multiple myeloma (NDMM), who are eligible for autologous stem cell transplant (ASCT). This authorization provides a new four-drug therapeutic option at the initial diagnosis stage, thereby potentially enhancing patient outcomes.
Get Instant Access to the Global Daratumumab Or Darzalex Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report
Which Key Segments Define the Structure of the Daratumumab Or Darzalex Market and Their Growth Potential?
The daratumumab or darzalexmarket covered in this report is segmented –
1) By Drug Type: 100Mg Injection; 400Mg Injection
2) By Distribution Channel: Pharmacies; Hospital; Other Distribution Channels
3) By Application: Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Diffuse Large B Cell Lymphoma; Other Applications
What Regions Are Propelling Growth in the Daratumumab Or Darzalex Industry?
North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does the Definition of the Daratumumab Or Darzalex Market Include?
Daratumumab, or darzalex, refers to a monoclonal antibody used as a medication in the treatment of certain cancers, particularly multiple myelomas. It is designed to target and bind to CD38, a protein that is highly expressed on the surface of multiple myeloma cells, as well as other malignant and normal immune cells.
Browse Through More Similar Reports By The Business Research Company:
Antibody Contract Manufacturing Global Market Report 2025
Next-Generation Antibody Therapeutics Global Market Report 2025
Antibody Drug Conjugates Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
